Pharmacokinetics and safety of teriparatide in dialysis patients with osteoporosis
Not Applicable
Recruiting
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000018714
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
*Patients with asthmatic diathesis and *Patients who develop a rash or symptom of irritation easily *Patients out of the reference ranges of ionized calcium or corrected calcium *Pregnant patients *Patients with severe cardiac or hepatic disease *Patients with dementia or psychiatric disease *Transplant recipients *Patients whose doses or kinds of antihypertensive drug were changed within the previous 2 weeks *Patients with high risk of osteosarcoma *Patients with primary or metastatic bone tumor *Patients who had been treated with teriparatide over 72 weeks *Patients regarded as inappropriate by researchers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the concentration of 1-34 PTH
- Secondary Outcome Measures
Name Time Method safety serial trends of bone turnover markers